Biopharma company Omeros (NSDQ:OMER) said that it closed a $68.3 million underwritten public offering last week, selling 3 million shares of its common stock at $22.75 apiece. After deducting fees and other expenses, Omeros said it is slated to reel in $63.6 million from the offering. The company plans to use its newly-acquired funds to […]
Featured
Novartis launches MS study using data collected from smartphones
Novartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing people with multiple sclerosis. The study is designed to collect data from physical tasks and symptoms using participants’ smartphones. The company said it hopes to find new potential ways to measure treatment effectiveness. The elevateMS study, developed with […]
Dexcom touts continuous glucose monitoring for Type II diabetes patients
Dexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring. Those in the 158-patient study using Dexcom’s G4 Platinum CGM system experienced significant A1C reduction and spent more time in target range compared to a control group […]
Tool identifies diabetes patients at risk for severe hypoglycemia
Researchers have developed a tool used to identify diabetes patients who are at-risk for being admitted to the hospital due to severe hypoglycemia, according to a study published today in JAMA Internal Medicine. “Sometimes a person with diabetes is unaware that their blood sugar is dropping and can progress quickly into severe hypoglycemia, which has been […]
Researchers progress towards vaccine against fentanyl, heroin combo
Researchers reported at the 254th National Meeting & Exposition of the American Chemical Society today that they are developing a vaccine to guard against the effects of fentanyl in combination with heroin – a deadly duo that is claiming a growing number of lives as the opioid crisis worsens in the U.S. “There is an […]
Gamida Cell launches severe aplastic anemia trial
Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating […]
BTG helps fund immuno-oncology drug-device research programs
BTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program. The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer. The program is specifically looking to fund proposals that assess how interventional […]
IBM partners to identify risk factors for Type I diabetes
IBM (NYSE:IBM) plans to develop and apply machine learning techniques to years of research data in the hopes of identifying factors that trigger the onset of Type I diabetes in children, with the support of JDRF. Scientists at IBM are slated to assess three different data sets using machine learning algorithms to find patterns and factors […]
South Carolina becomes latest state to sue opioid-maker Purdue
On Tuesday this week, South Carolina became the latest state to sue Purdue Pharma, accusing the drugmaker of deceptively marketing their addictive products in a way that fueled the ongoing opioid crisis. The state’s attorney general said that Purdue told doctors that opioids are not addictive and patients who appear to be addicted were only […]
Medtech stories we missed this week: Aug. 18, 2017
From Nemaura’s new Oceania distribution deal to Sanuwave’s promissory note expansion, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Nemaura inks Oceania distribution deal for SugarBeat patch Nemaura announced in an Aug. 15 press release that it has signed a non-binding distribution deal with Device Technologies for […]